Total Payments
$1.6M
2024 Payments
$219,247
Companies
26
Transactions
1,000
Medicare Patients
247
Medicare Billing
$44,371
Payment Breakdown by Category
Other$692,114 (44.6%)
Consulting$522,291 (33.7%)
Travel$157,009 (10.1%)
Research$151,038 (9.7%)
Food & Beverage$27,883 (1.8%)
Education$1,040 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $688,662 | 199 | 44.4% |
| Consulting Fee | $522,291 | 134 | 33.7% |
| Travel and Lodging | $157,009 | 309 | 10.1% |
| Unspecified | $151,038 | 19 | 9.7% |
| Food and Beverage | $27,883 | 329 | 1.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,552 | 1 | 0.2% |
| Education | $1,040 | 8 | 0.1% |
| Honoraria | $900.00 | 1 | 0.1% |
Payments by Type
General
$1.4M
981 transactions
Research
$151,038
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $341,805 | 264 | $0 (2024) |
| Genentech USA, Inc. | $264,359 | 143 | $0 (2024) |
| EMD Serono, Inc. | $219,527 | 221 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $182,299 | 128 | $0 (2024) |
| EMD Serono Research & Development Institute, Inc. | $131,639 | 7 | $0 (2024) |
| TG Therapeutics, Inc. | $117,752 | 65 | $0 (2024) |
| Genentech, Inc. | $72,223 | 39 | $0 (2024) |
| GENZYME CORPORATION | $66,838 | 37 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $41,993 | 21 | $0 (2019) |
| Novartis Pharma AG | $36,868 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $219,247 | 108 | TG Therapeutics, Inc. ($80,219) |
| 2023 | $308,043 | 147 | EMD Serono Research & Development Institute, Inc. ($82,289) |
| 2022 | $148,967 | 84 | Genentech USA, Inc. ($47,370) |
| 2021 | $144,492 | 89 | Genentech USA, Inc. ($55,006) |
| 2020 | $52,277 | 30 | Genentech USA, Inc. ($33,435) |
| 2019 | $239,306 | 186 | Biogen, Inc. ($102,529) |
| 2018 | $237,961 | 199 | Biogen, Inc. ($83,460) |
| 2017 | $201,081 | 157 | Biogen, Inc. ($44,303) |
All Payment Transactions
1,000 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,240.00 | General |
| 12/19/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $146.88 | General |
| 12/17/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $6,900.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $2,415.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $132.32 | General |
| 12/16/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $219.52 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: Neurology | ||||||
| 12/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 12/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | In-kind items and services | $891.34 | General |
| Category: Immunology | ||||||
| 12/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $114.28 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,520.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $1,552.50 | General |
| Category: Immunology | ||||||
| 12/05/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $245.83 | General |
| 12/04/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $5,300.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $60.47 | General |
| 12/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $45.75 | General |
| 11/21/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,520.00 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | In-kind items and services | $820.00 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | In-kind items and services | $356.96 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | In-kind items and services | $347.85 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $121.65 | General |
| Category: Immunology | ||||||
| 11/14/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $596.30 | General |
| 11/14/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $575.83 | General |
| 11/14/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $245.79 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | EMD Serono Research & Development Institute, Inc. | $105,210 | 5 |
| An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | TG THERAPEUTICS, INC. | $14,700 | 3 |
| Independent Endpoint Adjudication Committee (IEAC) for Evobrutinib | EMD Serono Research & Development Institute, Inc. | $13,752 | 1 |
| A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | EMD Serono, Inc. | $6,764 | 1 |
| An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | TG Therapeutics, Inc. | $3,600 | 1 |
| Independent Endpoint Adjudication Committee (IEAC) for Evobrutinib Phase III MSstudy MS200527-0080 & 0082 | EMD Serono, Inc. | $1,935 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | SANOFI-AVENTIS U.S. LLC | $1,640 | 4 |
| Design of a Real-World, Non-Interventional Study Evaluating the Usability and Value of Integrated Digital Solutions for Routine Care of Patients with Multiple Sclerosis. | F. Hoffmann-La Roche AG | $1,589 | 1 |
| ILLUMINATE: a real-world, non-interventional study evaluating the usability and value of integrated digital solutions for routine care of patients with multiple sclerosis | F. Hoffmann-La Roche AG | $1,390 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | GENZYME CORPORATION | $458.31 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 61 | 93 | $45,090 | $11,477 |
| 2022 | 2 | 62 | 89 | $42,470 | $10,552 |
| 2021 | 2 | 55 | 94 | $45,070 | $11,957 |
| 2020 | 3 | 69 | 114 | $43,480 | $10,386 |
Total Patients
247
Total Services
390
Medicare Billing
$44,371
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 59 | $25,370 | $6,367 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 34 | $19,720 | $5,110 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 61 | $26,230 | $6,608 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 28 | $16,240 | $3,944 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 63 | $27,090 | $6,658 | 24.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 31 | $17,980 | $5,299 | 29.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 37 | 57 | $24,510 | $5,021 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 28 | $11,480 | $2,690 | 23.4% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 21 | 29 | $7,490 | $2,674 | 35.7% |
About Dr. Stephen Krieger, MD
Dr. Stephen Krieger, MD is a Neurology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417023367.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Krieger, MD has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $219,247 received in 2024. These payments were reported across 1,000 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($688,662).
As a Medicare-enrolled provider, Krieger has provided services to 247 Medicare beneficiaries, totaling 390 services with total Medicare billing of $44,371. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location New York, NY
- Active Since 11/24/2006
- Last Updated 10/14/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417023367
Products in Payments
- BRIUMVI (Drug) $115,852
- OCREVUS (Biological) $64,865
- Ocrevus (Biological) $63,057
- GILENYA (Drug) $43,748
- COPAXONE (Drug) $21,431
- LAQUINIMOD (Drug) $20,561
- ACTHAR (Biological) $18,856
- TYSABRI (Biological) $17,852
- FTY720D (Drug) $15,908
- MAYZENT (Drug) $15,091
- Mavenclad (Biological) $14,904
- DISEASE STATE (Drug) $14,595
- NITYR (Drug) $13,125
- KESIMPTA (Drug) $12,849
- Rebif (Biological) $11,443
- ARZERRA (Drug) $9,317
- AMPYRA (Drug) $6,377
- NO PRODUCT DISCUSSED (Drug) $6,104
- Evobrutinib $5,300
- Ozanimod (Drug) $4,982
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New York
Dr. David Dodick, M.d, M.D
Neurology — Payments: $765,174
Neurology $765,174
Dr. David Simpson, M.d, M.D
Neurology — Payments: $638,492
Neurology $638,492
Steven Wolf, Md, MD
Neurology — Payments: $585,108
Neurology $585,108
Dr. Alexander Shtilbans, Md, Ph.d, MD, PH.D
Neurology — Payments: $550,165
Neurology $550,165
Dr. Fred Lublin, M.d, M.D
Neurology — Payments: $549,390
Neurology $549,390
Dr. Alcibiades Rodriguez, Md, MD
Neurology — Payments: $540,659
Neurology $540,659